Entactogen: Difference between revisions
>Oskykins m Text replace - "Effect:Thought acceleration" to "Thought acceleration" |
>Blackhole m Reverted edits by MountainTraveler (talk) to last revision by Unity |
||
(41 intermediate revisions by 13 users not shown) | |||
Line 1: | Line 1: | ||
'''Entactogens''' (also known as '''empathogens''') are a class of [[psychoactive substances]] that produce distinctive emotional and social effects similar to those of [[MDMA]]. | |||
The term "'''empathogen'''" was coined in 1983 by Ralph Metzner to denote chemical agents capable of inducing feelings of empathy. "'''Entactogen'''" was coined by [[David E. Nichols]] as an alternative to "empathogen," attempting to avoid the potential for an improper association of the latter with negative connotations related to the Greek root "pathos" (''suffering''). | |||
== | ==Etymology== | ||
The term ''empathogen'', meaning "generating a state of empathy", was coined in 1983–84 independently by [[Ralph Metzner]] and [[David E. Nichols]] as a term to denote a therapeutic class of drugs that includes [[MDMA]] and phenethylamine relatives.<ref>{{cite book|editor-last=Holland|editor-first=Julie|last1=Metzner|first1=Ralph|last2=Adamson|first2=Sophia|title=Ecstasy : the complete guide ; a comprehensive look at the risks and benefits of MDMA|date=2001|publisher=Park Street Press|location=Rochester, Vt|isbn=978-0-89281-857-0|page=182|ref=CompleteGuide}}</ref> Nichols later rejected this initial terminology and adopted, instead, the term ''entactogen'', meaning "touching within", to denote this class of drugs, asserting a concern with the potential for improper association of the term ''empathogen'' with negative connotations related to the Greek root πάθος ''páthos'' ("suffering").<ref name=Nichols86>{{cite journal|last1=Nichols|first1=D.|title=Differences Between the Mechanism of Action of MDMA, MBDB, and the Classic Hallucinogens. Identification of a New Therapeutic Class: Entactogens|journal=Journal of Psychoactive Drugs|date=1986|volume=18|issue=4|pages=305–13|doi=10.1080/02791072.1986.10472362|pmid=2880944}}<!--|accessdate=6 January 2015--></ref> Additionally, Nichols wanted to avoid any association with the term pathogenesis.<ref name=":0">{{Cite book|url=http://www.oxfordreference.com/view/10.1093/acref/9780199657681.001.0001/acref-9780199657681|title=Dictionary of Psychology - Oxford Reference|doi=10.1093/acref/9780199657681.001.0001|year=2015|isbn=9780199657681|last1=Colman|first1=Andrew M.}}</ref> | |||
Nichols also thought the original term was limiting, and did not cover other therapeutic uses for the drugs that go beyond instilling feelings of empathy.<ref name=Nichols93>{{cite journal|last1=Nichols|first1=D|last2=Yensen|first2=R|last3=Metzner|first3=R|last4=Shakespeare|first4=W|title=The Great Entactogen - Empathogen Debate|journal=Newsletter of the Multidisciplinary Association for Psychedelic Studies MAPS|date=1993|volume=4|issue=2|pages=47–49|url=http://www.maps.org/news-letters/v04n2/04247eed.html|accessdate=6 January 2015}}</ref> The hybrid word ''entactogen'' is derived from the roots ''en'' (|within), ''tactus'' (touch) and ''-gen'' (produce).<ref name=Nichols86/> Neither term is dominant in usage, and, despite their difference in connotation, they are essentially interchangeable, as they refer to precisely the same chemicals. | |||
==History and culture== | |||
{{historyStub}} | |||
{{quote|text="Therapists used entactogens such as MDMA in their practice before it was criminalized in 1985. Since that time, much effort has taken place to conduct government-approved scientific research into MDMA's therapeutic potential, which has recently been demonstrated in placebo-controlled studies of MDMA-assisted psychotherapy for subjects with chronic, treatment-resistant posttraumatic stress disorder."|sign=Ralph Metzner, Ph.D.|source=[https://store.maps.org/np/clients/maps/product.jsp?product=801 MAPS]}} | {{quote|text="Therapists used entactogens such as MDMA in their practice before it was criminalized in 1985. Since that time, much effort has taken place to conduct government-approved scientific research into MDMA's therapeutic potential, which has recently been demonstrated in placebo-controlled studies of MDMA-assisted psychotherapy for subjects with chronic, treatment-resistant posttraumatic stress disorder."|sign=Ralph Metzner, Ph.D.|source=[https://store.maps.org/np/clients/maps/product.jsp?product=801 MAPS]}} | ||
==Subjective effects== | ==Subjective effects== | ||
{{Preamble/SubjectiveEffects}} | |||
These effects are listed and defined in their own dedicated article below: | |||
*'''[[Anxiety suppression]]''' | |||
*'''[[Disinhibition]]''' | |||
*'''[[Empathy, affection, and sociability enhancement]]''' | |||
Alongside of these, a variety of secondary effects are often present. These generally include (but are not limited to): | |||
*'''[[Stimulation]]''' | |||
*'''[[Cognitive euphoria|Euphoria]]''' | |||
*'''[[Thought acceleration]]''' | |||
*'''[[Introspection]]''' | |||
==List of entactogens== | |||
The compounds below have varying degrees of entactogenic effects. Some of the chemicals have a minimal entactogenic effect while others may have a strong entactogenic effect. Many of these substances possess other effects including [[Stimulants|stimulant]] effects and [[Psychedelics|psychedelic]] effects. | |||
*[[1,4-Butanediol]] | |||
*[[2C-B]] | |||
*[[2C-I]] | |||
*[[3-FEA]] | |||
*[[3-MMC]] | |||
*[[4-FA]] | *[[4-FA]] | ||
*[[5-APB]] | *[[5-APB]] | ||
*[[5-APDB]] | *[[5-APDB]] | ||
*[[6-APB]] | *[[5-EAPB]] | ||
*[[5-EAPDB]] | |||
*[[5-MAPB]] | |||
*[[5-MAPDB]] | |||
*[[5-MAPDI]] | |||
*[[5-MeO-DALT]] | |||
*[[5-MeO-DiPT]] | |||
*[[5-MeO-MiPT]] | |||
*[[6-APB]] (''Benzo fury'') | |||
*[[6-APDB]] | *[[6-APDB]] | ||
*[[ | *[[6-EAPB]] | ||
*[[ | *[[6-EAPDB]] | ||
*[[ | *[[6-MAPB]] | ||
*[[ | *[[6-MAPDB]] | ||
*[[ | *[[αMT]] | ||
*[[Butylone]] | |||
*[[GBL]] | |||
*[[GHB]] | |||
*[[IBF5MAP]] | |||
*[[MBDB]] | *[[MBDB]] | ||
*[[MDA]] | *[[MDA]] | ||
*[[MDAI]] | |||
*[[MDEA]] | *[[MDEA]] | ||
*[[MDMA]] | *[[MDMA]] | ||
Line 37: | Line 63: | ||
*[[Methylone]] | *[[Methylone]] | ||
*[[MMA]] | *[[MMA]] | ||
*[[ | *[[MMDA]] | ||
*[[ | *[[PMA]] | ||
*[[ | *[[PMMA]] | ||
==See | ==See also== | ||
*[[Responsible use]] | |||
*[[Stimulants]] | *[[Stimulants]] | ||
*[[Psychedelics]] | *[[Psychedelics]] | ||
*[[Empathy, love, and sociability enhancement]] | |||
*[[MDMA]] | |||
==External links== | |||
* [https://en.wikipedia.org/wiki/Empathogen%E2%80%93entactogen Empathogen–entactogen (Wikipedia)] | |||
==Literature== | |||
* Nichols, D.E., Hoffman, A.J., Oberlender, R.A., Jacob P 3rd & [[Alexander Shulgin|Shulgin A.T.]] Derivatives of 1-(1,3-benzodioxol-5-yl)-2-butanamine: representatives of a novel therapeutic class. 1986. J Med Chem 29. 2009-15. | |||
* Nichols, D.E. Differences between the mechanism of action of MDMA, MBDB, and the classic hallucinogens. Identification of a new therapeutic class: entactogens. 1986. J Psychoactive Drugs 18. 305-13. | |||
==References== | ==References== | ||
[[Category:Psychoactive class]] | |||
[[Category:Entactogen|*]] |